Iovance Biotherapeutics is trading at $14.42, up 4.64%, during October 27, 2026 trading, with no clear company-specific catalyst confirmed for the rise.
- The company announced it will report third-quarter results on November 5; this scheduled future event does not explain today’s move.
- ESMO results released October 26 showed lifileucel had a 50% confirmed response rate among the first eight evaluable soft-tissue-sarcoma patients. Available evidence does not establish that news caused today’s gain.